Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Apellis Pharmaceuticals (APLS) over the last 6 years, with Dec 2024 value amounting to -$403,000.

  • Apellis Pharmaceuticals' Cash from Investing Activities was N/A to -$148,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$225,000, marking a year-over-year change of. This contributed to the annual value of -$403,000 for FY2024, which is 40.21% up from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Cash from Investing Activities is -$403,000, which was up 40.21% from -$674,000 recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Cash from Investing Activities ranged from a high of $247.6 million in FY2021 and a low of -$317.0 million during FY2020.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$403,000 (2024), whereas its average is $19.6 million.
  • In the last 5 years, Apellis Pharmaceuticals' Cash from Investing Activities tumbled by 18,623.51% in 2020 and then surged by 178.12% in 2021.
  • Yearly analysis of 5 years shows Apellis Pharmaceuticals' Cash from Investing Activities stood at -$317.0 million in 2020, then spiked by 178.12% to $247.6 million in 2021, then tumbled by 75.81% to $59.9 million in 2022, then tumbled by 101.13% to -$674,000 in 2023, then skyrocketed by 40.21% to -$403,000 in 2024.